Razi Cov Pars
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular, Intranasal |
Legal status | |
Legal status |
Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3]
It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7]
Contents
Medical uses[edit]
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]
Pharmacology[edit]
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]
Manufacturing[edit]
It's planned to produce one million doses of the vaccine each month as of September 2021.[4]
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8]
History[edit]
Clinical trials[edit]
Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
---|---|---|---|---|---|---|---|
Total | Vaccine | Placebo | |||||
I | IRCT20201214049709N1 | 21 January 2021 | 133 | 30 (5 µg/200µL)
30 (10 µg/200µL) 30 (20 µg/200µL) |
30 (placebo)
13 (sentinel) |
18-50 years | [2] |
II | IRCT20201214049709N2 | 13 April 2021 | 500 | 18-70 years | [3] | ||
III | IRCT20201214049709N3 | 29 August 2021 | 41,128 | 20,564 | 0 (placebo)
20,564 (Sinopharm BIBP vaccine) |
18+ years | [5] |
Authorizations[edit]
Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.[6][7]
See also[edit]
References[edit]
- ^ a b Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
- ^ a b c "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
{{cite web}}
: CS1 maint: url-status (link) - ^ a b c "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
{{cite web}}
: CS1 maint: url-status (link) - ^ a b "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
- ^ a b "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
- ^ a b "مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد". ایسنا (in Persian). 31 October 2021. Retrieved 27 November 2021.
- ^ a b "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 27 November 2021.
- ^ "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد". ایسنا (in Persian). 25 November 2021. Retrieved 27 November 2021.
Scholia has a profile for Razi Cov Pars (Q106725976). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- CS1 maint: url-status
- CS1 Persian-language sources (fa)
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from April 2021
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Articles containing Persian-language text
- All stub articles